2009 News Archive
November 5, 2009
The IRB recently lost an important member of the staff. Jeanette Cuthbert has left us. We would like to thank Jeanette for the many years of service she has provided, not only to us, but also to all of you. We hope the future holds many wonderful things for her.
In her place, the IRB is excited to welcome Josi Wood! Josi is very ambitious and eager to help resolve all of your IRB questions and issues.
September 17, 2009
HHS & FDA Institutional Review Board Registration Requirements
On July 14, 2009, the new Department of Health and Human Services (HHS) and Food and Drug Administration (FDA) regulations requiring registration of institutional review boards (IRBs) that were published in the Federal Register on January 15, 2009 (74 FR 2399 and 74 FR 2358) will go into effect. The Office for Human Research Protections' (OHRP's) IRB registration system will be compatible with the requirements of both the HHS and FDA regulations.
The University of Utah IRB registration information for HHS and FDA is as follows:
- Assurance: FWA00003745 - U Utah
- Expiration: November 6, 2011
- Panel 1 ID: IRB00000104 - U of Utah IRB #1
- Panel 2 ID: IRB00000105 - U of Utah IRB #2
- Panel 3 ID: IRB00000106 - U of Utah IRB #3
- Panel 4 ID: IRB00000107 - U of Utah IRB #4
- Panel 5 ID: IRB00006644 - U of Utah IRB #5
May 1, 2009
The IRB has recently received an increased volume of submissions, with nearly double the amount of reviews for the meetings in May. Due to the number of submissions that require review, some IRB applications will be bumped back 1 - 2 board meetings.
The IRB is assigning studies according to the following guidelines and there is no guarantee of a specific meeting date at this time. Studies must complete and submit pre board revisions before they will be considered for meeting assignment.
New Studies and Amendments
Priority for review goes to:
- Studies that have already been bumped from a prior meeting
- Studies that have completed and submitted pre board revisions the earliest
- Studies for which the IRB has specific reviewing expertise
Continuing Review Applications:
For For continuing review applications that do not expire within the month of May, we will be bumping a significant portion to meetings throughout June in order to accommodate studies with more urgent expiration dates. See assignment schedule below:
|Expiration Date||Assign to Panel:|
|Any time in May||Panel 2 - May meeting
Panel 3 - May meeting
Panel 4 - May meeting
|June 1-15, 2009||Panel 4 - May meeting|
|June 16-30, 2009||Panel 1 - June meeting|
|July 1-15, 2009||Panel 2 - June meeting|
|July 16-30, 2009||Panel 3 - June meeting|
|Aug 1-15, 2009||Panel 4 - June meeting|
We hope to be back on schedule by the beginning of June and apologize for any inconvenience. If you have any questions or concerns, please contact the IRB at 801-581-3655 or IRB@hsc.utah.edu.
April 16, 2009
The IRB has updated the Tissue Banking Consent Language Template. The new version can be found on the IRB website.
This new template should be used by all investigators when writing consent documents that involve the collection of tissues for storage in a tissue repository, whether the repository is housed at the University of Utah or at an outside entity.
Please note that all tissue banking language used from the old template is still compliant with this new template and no changes need to be made at continuing review. However, an investigator can choose to follow the new format and an amendment would need to be submitted to revise the consent document.
The IRB has also created an online resource for investigators who are conducting studies that involve tissue collection, use, and repositories. The online resource has been posted on the our website and can be found on this page.
This resource provides information on the following topics:
Tissue Collection and Use
- Review Process for Tissue Collection and Use
- Consent and Authorization for Tissue Collection and Use
- Samples Collected for Non-Research Purposes(Pathology Samples)
- Autopsy Samples
- Publicly Available Tissue Samples
- Sharing Samples with Other Institutions
- VA Policies for Tissue Collection and Use
- Why Create or Use a Research Tissue Repository?
- Developing and Maintaining a Tissue Repository
- Review Process for Tissue Repositories
- Consent and Authorization for Tissue Repositories
- VA Policies for Tissue Repositories
- Using Samples from a Tissue Repository
Additional Resources and Guidance
- Genetic Research
- Human Tissue Transfer
- Tissue Banking Template Consent Language
March 27, 2009
RGE Application in ERICA
Beginning Sunday, March 29th, users who are requesting permission to use the Utah Population Database (UPDB) will be required to submit an application to RGE via the ERICA system. The RGE application has been incorporated into the IRB New Study Application and users will be prompted to complete the RGE application when they indicate the use of UPDB in the IRB application (question 4.2c).
This feature will allow the RGE application to be submitted with the IRB application when the PI clicks "Submit to the IRB", eliminating the need to submit both application separately. Please note that these are still two different application that require two separate reviews. RGE will review the study and must approve it before it will move on to the IRB for review.
PCMC Privacy Board Review in ERICA
Beginning Sunday, March 29th, for studies that require review by the PCMC Privacy Board, the process will now be completed entirely in the ERICA system. This eliminates the need for a separate application to be submitted to the PCMC Privacy Board (via the Intermountain Healthcare IRB). The Privacy Board will use the current IRB application in addition to the PCMC Administrative Research Questions, which are already requested as part of the IRB application.
Please note that these are still two separate reviews. The Privacy Board will review the study and must approve it before it will move on to the IRB for review.
February 17, 2009
Protocol and Research Summary Template Changes
The IRB has posted new versions of the Protocol and Research Summary templates.
Change 1: The title page of the Protocol and Research Summary templates now requests that contact information for the sponsor and CRO of a study be included. This will need to be revised for all applicable protocol and re4search summaries at a study's next continuing review.
Change 2: Various sections throughout the Protocol and Research Summary templates now request information regarding the use of the Utah Population Database (UPDB). The RGE Committee will be using the IRB Protocol and Research Summary templates in their review for the use of UPDB. If this information is not provided in a current study's protocol or research summary, it will need to be revised at the study's next continuing review.
Change 3: The Administrative Responsibilities section now requests that contact information for participating sites be included with the IRB application for studies where the University of Utah is the lead site. This list does not need to be provided for multi-center studies where the University of Utah is not the lead site. This will need to be revised for all protocol and research summaries at a study's next continuing review.
New templates have been posted on the IRB website. Tracked copies of these templates are posted as well in order for you to easily view the changes.
If you have any questions about these changes, please feel free to contact the IRB.
February 2, 2009
Justification for Use of the Short Form
When an informed consent process is conducted with an individual who does not speak English, participants should be presented with the consent document written in a language understandable to them. The IRB strongly encourages the use of this procedure whenever possible. However, the Short Form is often used as a method to consent non-English speaking participants into research, using an oral consent process, without the full translation of the consent document. For full instructions on the purpose of the use of the Short Form, please refer to the IRB guidance.
Because using a full, translated consent is the preferred method, the IRB will now be requesting that justification for the use of the Short Form be provided in the New Study Application. A question has been added to the New Study Application to request this justification. Please click here for the New Study Application changes.
Please not that all studies previously approved to use the Short Form will not be reassessed for justification. All studies with a currently approved Short Form may continue with this consent process.
If you have any questions about these changes, please feel free to contact the IRB.
January 27, 2009
Witness Signature Page
The IRB has recently created a witness signature page. The witness signature page is intended to be used in unanticipated situations when a participant is able to give full consent for participation in a research study, however, a witness to the consent process is necessary. Such situations may include:
- The participant is illiterate and must have the consent document read aloud.
- The participant is blind and must have the consent document read aloud.
- The participant is physically unable to write and cannot sign the consent document.
IRB approval for use of the witness signature page is not needed. This page may be printed for use at any time there is an unanticipated need for a witness to the consent process.
The witness signature page should not be used for studies that are required to have a witness present or for studies that anticipate a large portion of the participant population will require a witness to the consent process. For these studies, the witness signature lines should be included on the signature page of the full, IRB approve consent document.
The witness signature page must not be used for the following situations:
- Consenting individuals who do not read or speak English as their primary language.
- Consenting individuals who are cognitively impaired or mentally disabled.
- Consenting minors without parental permission.
Any study found to be using the witness signature page for these purposes will be non-compliant with IRB policy.
You can find a copy of the witness signature page on the IRB website.